19 research outputs found
Supplemental material for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial
No full textSupplemental Material3 for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial by Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen and Lars Bendtsen in Cephalalgia</p
Economic benefits of treating medication-overuse headache – results from the multicenter COMOESTAS project
Get PDFBackground: Medication-overuse headache is a costly disease for individuals and society.
Objective: To estimate the impact of medication-overuse headache treatment on direct and indirect headache-related
health care costs.
Methods: This prospective longitudinal study was part of the COMOESTAS project (COntinuous MOnitoring of
Medication Overuse Headache in Europe and Latin America: development and STAndardization of an Alert and decision
support System). Patients with medication-overuse headache were included from four European and two Latin American
headache centers. Costs of acute medication, costs of health care services, and measurements of productivity were
calculated at baseline and at 6-month follow-up Treatment consisted of overused drug withdrawal with optional preventive medication.
Results: A total of 475 patients (71%) completed treatment and were followed up for 6 months. Direct health care
costs were on average reduced significantly by 52% (p < 0.001) for the total study population. Significant reductions were
seen in both number of consumed tablets (71%, p < 0.001) and number of visits to physicians (43%, p < 0.001). Fifty
percent of patients reduced their number of consumed tablets 80%. Headache-related productivity loss, calculated
either as absence from work or 50% reduction of productivity during the workday, were reduced by 21% and 34%,
respectively (p < 0.001).
Conclusion: Standardized treatment of medication-overuse headache in six countries significantly reduced direct health
care costs and increased productivity. This emphasizes the importance of increasing awareness of the value of treating
medication-overuse headache
Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study
Get PDFMedication overuse headache sub-diagnosis and duration of medication overuse. The table characterizes the medication overuse headache (MOH) sub-diagnosis. Results are shown as percent of patients with a specific MOH sub-diagnosis. Numbers in brackets presents the proportion of the patient population that used a specific analgesics 30 days/month. p-values correspond to comparison of MOH sub-diagnosis between Europe and Latin America. *p < 0.05. 1A patient can have more than one MOH sub-diagnosis. 2Intake of combination of acute medication ≥ 15 days/month without overuse of a single drug. (PDF 67 kb
Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project
Get PDFBackground: Medication-overuse headache is a costly disease for individuals and society.
Objective: To estimate the impact of medication-overuse headache treatment on direct and indirect headache-related health care costs.
Methods: This prospective longitudinal study was part of the COMOESTAS project (COntinuous MOnitoring of Medication Overuse Headache in Europe and Latin America: development and STAndardization of an Alert and decision support System). Patients with medication-overuse headache were included from four European and two Latin American headache centers. Costs of acute medication, costs of health care services, and measurements of productivity were calculated at baseline and at 6-month follow-up Treatment consisted of overused drug withdrawal with optional preventive medication.
Results: A total of 475 patients (71%) completed treatment and were followed up for 6 months. Direct health care costs were on average reduced significantly by 52% ( p < 0.001) for the total study population. Significant reductions were seen in both number of consumed tablets (-71%, p < 0.001) and number of visits to physicians (-43%, p < 0.001). Fifty percent of patients reduced their number of consumed tablets ≥ 80%. Headache-related productivity loss, calculated either as absence from work or ≥ 50% reduction of productivity during the workday, were reduced by 21% and 34%, respectively ( p < 0.001).
Conclusion: Standardized treatment of medication-overuse headache in six countries significantly reduced direct health care costs and increased productivity. This emphasizes the importance of increasing awareness of the value of treating medication-overuse headache.Fil: Jellestad, Pernille Linde. Rigshospitalet Glostrup; Dinamarca.Fil: Ninett Carlsen, Louise. Rigshospitalet Glostrup; Dinamarca.Fil: Westergaard, Maria Lurenda. Rigshospitalet Glostrup; Dinamarca.Fil: Munksgaard, Signe Bruun. Rigshospitalet Glostrup; Dinamarca.Fil: Bendtsen, Lars. Rigshospitalet Glostrup; Dinamarca.Fil: Lainez, Miguel J. A. Pontificia Catolica University of Chile; Chile.Fil: Fadic, Ricardo. Foundation of the Valencian Community; España.Fil: Katsarava, Zaza. University of Essen; Alemania.Fil: Goicochea, María Teresa. Fleni. Departamento de Neurología. Clínica del Dolor. Clínica de Cefaleas; Argentina.Fil: Spadafora, Santiago. Universidad ISalud; Argentina.Fil: Højland Jensen, Rigmor. Rigshospitalet Glostrup; Dinamarca.Fil: Nappi, Giuseppe. Mondino National Neurological Institute; Italia. University of Pavia; Italia
Aquaporins in pancreatic ductal adenocarcinoma
No full textAquaporins are water channel proteins facilitating passive transport of water across cellular membranes. Aquaporins are over- or ectopically expressed in a multitude of cancers, including pancreatic ductal adenocarcinoma, which is a highly aggressive cancer with low survival rate. Evidence suggests that aquaporins can affect multiple cellular processes involved in cancer development and progression including epithelial-mesenchymal transition, cellular migration, cell proliferation, invasion, and cellular adhesions. In pancreatic ductal adenocarcinoma, aquaporin-1, aquaporin-3, and aquaporin-5 are overexpressed and have been associated with metastatic processes and poor survival. Thus, aquaporin expression has been suggested as diagnostic markers and therapeutic targets in pancreatic ductal adenocarcinoma
Complete detoxification is the most effective treatment of medication-overuse headache:A randomized controlled open-label trial
No full textBackground There is lack of evidence on how to detoxify medication-overuse headache. Aim To compare the effect of complete stop of acute medication with restricted intake. Methods Medication-overuse headache patients were included in a prospective, outpatient study and randomized to two months' detoxification with either a) no analgesics or acute migraine-medication (program A), or b) acute medication restricted to two days/week (program B). Detoxification was followed by preventives if indicated. Patients were followed up at 2, 6 and 12 months. Percentage reduction in headache days/month after 6 months was the primary outcome. Results We included 72 medication-overuse headache patients with a primary migraine and/or tension-type headache diagnosis. Fifty-nine completed detoxification, 58 (81%) were followed up at month 6 and 53 (74%) at month 12. At month 6, program A reduced headache days/month by 46% (95% CI 34-58) compared with 22% (95% CI 11-34) in program-B ( p = 0.005), and 70% in program A versus 42% in program B were reverted to episodic headache ( p = 0.04). Migraine-days/month were reduced by 7.2 in program A ( p < 0.001) and 3.6 in program B ( p = 0.002) after 6 months. Conclusion Both detoxification programs were very effective. Detoxification without analgesics or acute migraine-medication was the most effective program. Trial registration Clinicaltrials.gov (NCT02903329).</p
